A Phase II Study of BKM120 (Buparlisib) in Relapsed or Refractory Thymomas
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 09 Mar 2018
At a glance
- Drugs Buparlisib (Primary)
- Indications Thymoma
- Focus Therapeutic Use
- 06 Mar 2018 Planned primary completion date changed from 1 Nov 2017 to 1 Nov 2018.
- 06 Mar 2018 Status changed from recruiting to active, no longer recruiting.
- 19 Oct 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.